Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

TAILORx Tissue Bank

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by ICORG- All Ireland Cooperative Oncology Research Group
Sponsor:
Information provided by (Responsible Party):
ICORG- All Ireland Cooperative Oncology Research Group
ClinicalTrials.gov Identifier:
NCT02050750
First received: January 24, 2014
Last updated: June 26, 2014
Last verified: January 2014
  Purpose

This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.


Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)

Resource links provided by NLM:


Further study details as provided by ICORG- All Ireland Cooperative Oncology Research Group:

Primary Outcome Measures:
  • Disease relapse, endocrine and/or chemotherapy resistance prognosis [ Time Frame: For duration of follow up, expected 10 years ] [ Designated as safety issue: No ]
    A biobank, TMAs and full face sections, will allow for the identification of candidate/novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance


Secondary Outcome Measures:
  • Signature/biomarkers [ Time Frame: For the duration of follow up, expected 10 years ] [ Designated as safety issue: No ]
    Validation of emerging signature/biomarkers


Estimated Enrollment: 690
Study Start Date: December 2013
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts
TAILORx ICORG 06-31
Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available

Detailed Description:

The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance.

The secondary objectives are:

  • To validate emerging signatures/biomarkers identified.
  • To develop new assays for the breast cancer clinic.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study population will consist only of patients that participated in the TAILORx ICORG 06-31 trial. These patients must have participated in trial arms relevant to ICORG 06-31 study and have adequate tumour tissue available.

Criteria

Inclusion Criteria:

  • Patients that were registered with the ICORG 06-31 TAILORx trial and participated in trial arms
  • Patients with adequate tumor tissue available
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02050750

Locations
Ireland
Bons Secours Hospital Recruiting
Cork, Ireland
Contact: Contact Person    021-4343703      
Principal Investigator: Brian Bird, Dr         
Cork University Hospital Recruiting
Cork, Ireland
Contact: Contact Person    021-4921301      
Principal Investigator: Seamus O'Reilly, Dr         
Letterkenny General Hospital Recruiting
Donegal, Ireland
Contact: Contact Person    074-9123798      
Principal Investigator: Karen Duffy, Dr         
Adelaide and Meath National Children's Hospital Tallaght Not yet recruiting
Dublin, Ireland, 24
Contact: Contact Person    01-4142000      
Principal Investigator: Janice Walshe, Dr         
Beaumont Hospital Recruiting
Dublin, Ireland, 9
Contact: Contact Person    01-8092680      
Principal Investigator: Arnold Hill, Prof         
Mater Misericordiae University Hospital Recruiting
Dublin, Ireland
Contact: Contact Person    01-8032000      
Principal Investigator: Cathy Kelly, Dr         
St James Hospital Recruiting
Dublin, Ireland, 8
Contact: Contact Person    01-4103546      
Principal Investigator: John Kennedy, Dr         
St Vincent Universtiy Hospital Recruiting
Dublin, Ireland, 4
Contact: Contact Person    01-2094725      
Principal Investigator: Susan Kennedy, Prof         
Principal Investigator: John Crown, Prof         
Galway University Hospital Recruiting
Galway, Ireland
Contact: Contact Person    091-544735      
Principal Investigator: Maccon Keane, Dr         
Midwestern Regional Hospital Recruiting
Limerick, Ireland
Contact: Contact Person    061-482542      
Principal Investigator: Rajnish Gupta, Prof         
Sligo General Hosptial Recruiting
Sligo, Ireland
Contact: Contact Person    071-9171111      
Principal Investigator: Michael Martin, Dr         
Waterford Regional Hospital Recruiting
Waterford, Ireland
Contact: Contact Person    051-848000      
Principal Investigator: Miriam O'Connor, Dr         
Sponsors and Collaborators
ICORG- All Ireland Cooperative Oncology Research Group
  More Information

No publications provided

Responsible Party: ICORG- All Ireland Cooperative Oncology Research Group
ClinicalTrials.gov Identifier: NCT02050750     History of Changes
Other Study ID Numbers: ICORG 12-30
Study First Received: January 24, 2014
Last Updated: June 26, 2014
Health Authority: Ireland: Health Information and Quality Authority

Keywords provided by ICORG- All Ireland Cooperative Oncology Research Group:
Must have registered with the ICORG 06-31 TAILORx trial

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on November 25, 2014